The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Amyloidosis: patient fitness determines therapeutic strategies
Giampaolo Merlini
• 22 Jun 2017
Giampaolo Merlini, MD from Scientific Institute Policlinico San Matteo, University of Pavia, Pavia, Italy provides an overview of amyloidosis treatment for different subsets of patients depending on levels of ‘fitness’. He outlines different modes of therapy including stem cell transplantation, chemotherapy and combined therapy including pomalidomide and dexamethasone which shows promising results. Recorded at the European Hematological Association (EHA) 2017 in Madrid, Spain.
